Brooke McCormick

Despite numerous trials, breast cancer immunotherapies have had a modest clinical impact, with only 2 approved drugs, highlighting inefficiencies in the clinical trial system.

Patients with alopecia areata (AA) face significant out-of-pocket costs for treatments, despite many having limited efficacy.

In part 2 of our interview, Diane Mahoney, PhD, DNP, FNP-BC, WHNP-BC, APRN, advocates for a multidisciplinary, community-centered approach to reduce ovarian cancer care disparities and stresses the need for ongoing exploration of social, biological, and environmental factors affecting health outcomes.

On this episode of Managed Care Cast, we're talking with Jason Spangler, MD, MPH, CEO of the Center for Innovation and Value Research on equity challenges within health technology assessment.

Ryan Jacobs, MD, lymphoma division director at Atrium Health Levine Cancer Institute, explains the design and objectives of the phase 2 CAPTIVATE study comparing ibrutinib and venetoclax in patients with chronic lymphocytic leukemia (CLL).

Diane Mahoney, PhD, DNP, FNP-BC, WHNP-BC, APRN, discusses her study on how social determinants of health impact the health perceptions of Black and Hispanic ovarian cancer survivors, highlighting significant health disparities.

Patients with intellectual disabilities experience inconsistent chronic obstructive pulmonary disease (COPD) consultations and higher rates of antibiotic prescriptions for asthma, highlighting the need for improved and tailored primary care management.

Patients with atrial fibrillation who use wearable devices, like Apple Watches and FitBits, report higher anxiety levels and increased health care usage than nonusers.

Patients with atopic dermatitis who use oral corticosteroids for more than 90 days have a slightly increased risk of adverse events like myocardial infarction and hyperlipidemia.

Chronic obstructive pulmonary disease (COPD) significantly heightens the risk of mortality and hospitalization in patients with heart failure with preserved ejection fraction (HFpEF).

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

Social determinants of health (SDOH) factors significantly impact the overall health perceptions of Black and Hispanic ovarian cancer survivors.

In this interview from our coverage of the European Hematology Association 2024 Congress, we spoke with Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd, executive vice president and chief medical officer of the CLL Society and himself a survivor of chronic lymphocytic leukemia (CLL), to discuss treatment advancements and the importance of addressing both unmet needs and patient treatment preferences.

Timothy Caulfield, JD, research director of the Health Law Institute at the University of Alberta, discusses strategies for building trust, overcoming cultural and language barriers, and enhancing interdisciplinary collaboration in pediatric dermatology at the Society of Pediatric Dermatology conference.

Ibrahim Aldoss, MD, of City of Hope, discusses promising phase 2 results of the WU-CART-007 trial, demonstrating high efficacy manageable safety for W-T7 in relapsed/refractory T-cell acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL).

Anna Sureda, MD, PhD, of the Catalan Institute of Oncology, discusses the evolving treatment landscape for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma.

A Danish study found that living in cities with fewer than 50,000 residents and in newer, owned, and less dense homes is associated with a lower risk of developing chronic obstructive pulmonary disease (COPD).

Patients with both diabetes and atherosclerotic cardiovascular disease (ASCVD) have about 1.5 times higher total direct health care expenditures than those without diabetes.

On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.

Today, the FDA approved roflumilast cream 0.15% (Zorvye; Arcutis Biotherapeutics) for the treatment of mild to moderate atopic dermatitis in patients 6 years and older.

Metformin use is linked to improved survival rates in patients with ovarian cancer, particularly among those with diabetes and serous cancers, though further research is needed to confirm these findings.

Patients with vitiligo have a higher genetic risk of developing rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

In the final part of our interview with Joseph Mikhael, MD, MEd, FRCPC, FACP, he addresses how patients who experience an early relapse of their multiple myeloma are predisposed to worse outcomes.

Glucagon-like peptide-1 (GLP-1) receptor agonists provide similar reductions in major adverse cardiovascular events, all-cause death, and cardiovascular-related death in patients with overweight and obesity who do not have diabetes and in patients with diabetes.

Minority patients with gynecologic cancers are more likely than White patients to receive treatment at academic facilities, a recent study found.

In part 2 of our interview with Suzanne Lentzsch, MD, PhD, Columbia University's College of Physicians and Surgeon, she touches on potential new therapies, important clinical considerations, and treatment challenge for relapsed/refractory multiple myeloma.

Based on the 2024 State of the Air report, Munaf Siyamwala, MD, of Centerpoint Medical Center, noted that patients with COPD need personalized action plans to manage flare-ups exacerbated by poor air quality and extreme weather conditions.

Researchers found no significant differences in disease-free survival, overall survival, and recurrence rates between fertility-sparing surgery and radical surgery for patients with stage I epithelial ovarian cancer.

Patients with atopic dermatitis, particularly males and those aged 40 to 59 years, have significantly higher rates of impaired mobility.